These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 25178825)

  • 1. Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation.
    Misra R; Das M; Sahoo BS; Sahoo SK
    Int J Pharm; 2014 Nov; 475(1-2):372-84. PubMed ID: 25178825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance.
    Meng T; Lu B; Shao S; Yuan M; Liu X; Yuan H; Huang X; Hu F
    Int J Pharm; 2017 Dec; 534(1-2):368-377. PubMed ID: 29051118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
    Ma X; Zhao Y; Ng KW; Zhao Y
    Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking.
    Li JM; Wang YY; Zhao MX; Tan CP; Li YQ; Le XY; Ji LN; Mao ZW
    Biomaterials; 2012 Mar; 33(9):2780-90. PubMed ID: 22243797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of multidrug resistance by reduction-sensitive linear cationic click polymer/iMDR1-pDNA complex nanoparticles.
    Gao Y; Chen L; Zhang Z; Chen Y; Li Y
    Biomaterials; 2011 Feb; 32(6):1738-47. PubMed ID: 21112086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using doxorubicin and siRNA-loaded heptapeptide-conjugated nanoparticles to enhance chemosensitization in epidermal growth factor receptor high-expressed breast cancer cells.
    Liu CW; Lin WJ
    J Drug Target; 2013 Sep; 21(8):776-86. PubMed ID: 23829387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.
    Misra R; Sahoo SK
    Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect.
    Chen M; Wang L; Wang F; Li F; Xia W; Gu H; Chen Y
    Int J Nanomedicine; 2019; 14():3557-3569. PubMed ID: 31190812
    [No Abstract]   [Full Text] [Related]  

  • 10. Restoration of chemosensitivity by multifunctional micelles mediated by P-gp siRNA to reverse MDR.
    Shen J; Wang Q; Hu Q; Li Y; Tang G; Chu PK
    Biomaterials; 2014 Oct; 35(30):8621-34. PubMed ID: 25002258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells.
    Dönmez Y; Gündüz U
    Biomed Pharmacother; 2011 Mar; 65(2):85-9. PubMed ID: 21237614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery.
    Gu J; Fang X; Hao J; Sha X
    Biomaterials; 2015 Mar; 45():99-114. PubMed ID: 25662500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-delivery of doxorubicin and RNA using pH-sensitive poly (β-amino ester) nanoparticles for reversal of multidrug resistance of breast cancer.
    Tang S; Yin Q; Zhang Z; Gu W; Chen L; Yu H; Huang Y; Chen X; Xu M; Li Y
    Biomaterials; 2014 Jul; 35(23):6047-59. PubMed ID: 24797883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution.
    Liu Y; Sun J; Lian H; Cao W; Wang Y; He Z
    J Pharm Sci; 2014 May; 103(5):1538-47. PubMed ID: 24619562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal effects of two new milbemycin compounds on multidrug resistance in MCF-7/adr cells in vitro.
    Gao A; Liang H; Wang X; Zhang X; Jing M; Zhang J; Yan Y; Xiang W
    Eur J Pharmacol; 2011 Jun; 659(2-3):108-13. PubMed ID: 21458446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
    J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance.
    Wang J; Sun J; Chen Q; Gao Y; Li L; Li H; Leng D; Wang Y; Sun Y; Jing Y; Wang S; He Z
    Biomaterials; 2012 Oct; 33(28):6877-88. PubMed ID: 22770799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance.
    Yhee JY; Song S; Lee SJ; Park SG; Kim KS; Kim MG; Son S; Koo H; Kwon IC; Jeong JH; Jeong SY; Kim SH; Kim K
    J Control Release; 2015 Jan; 198():1-9. PubMed ID: 25481438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.